Selling Your Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Stock? Here’s What You Need To Know

view original post

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares, rose in value on Thursday, 01/06/22, with the stock price up by 0.07% to the previous day’s close as strong demand from buyers drove the stock to $45.36.

Actively observing the price movement in the last trading, the stock closed the session at $45.33, falling within a range of $44.64 and $46.74. The value of beta (5-year monthly) was 1.09. Referring to stock’s 52-week performance, its high was $55.19, and the low was $28.40. On the whole, ITCI has fluctuated by 20.29% over the past month.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


With the market capitalization of Intra-Cellular Therapies Inc. currently standing at about $3.68 billion, investors are eagerly awaiting this quarter’s results, scheduled for Feb 23, 2022 – Feb 28, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.99, which is expected to increase to -$0.82 for fiscal year -$3.45 and then to about -$3.17 by fiscal year 2022. Data indicates that the EPS growth is expected to be -6.80% in 2022, while the next year’s EPS growth is forecast to be 8.10%.

Analysts have estimated the company’s revenue for the quarter at $24.94 million, with a low estimate of $23 million and a high estimate of $27.88 million. According to the average forecast, sales growth in current quarter could jump up 100.30%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $82.81 million, representing an increase of 263.00% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ITCI’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ITCI currently trading nearly 1.13% and 5.21% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.07, while the 7-day volatility ratio is showing 6.74% which for the 30-day chart, stands at 7.54%. Furthermore, Intra-Cellular Therapies Inc. (ITCI)’s beta value is 1.14, and its average true range (ATR) is 3.48.

A comparison of Intra-Cellular Therapies Inc. (ITCI) with its peers suggests the former has fared considerably weaker in the market. ITCI showed an intraday change of 0.07% in last session, and over the past year, it grew by 36.50%%. In comparison, Applied Genetic Technologies Corporation (AGTC) has moved lower at -1.09% on the day and was down -61.65% over the past 12 months. On the other hand, the price of MediciNova Inc. (MNOV) has fallen -4.38% on the day. The stock, however, is off -52.45% from where it was a year ago. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.10%. Meanwhile, the Dow Jones Industrial Slipped by -0.47%.

Data on historical trading for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) indicates that the trading volumes over the past 10 days have averaged 1.81 million and over the past 3 months, they’ve averaged 816.45K. According to company’s latest data on outstanding shares, there are 81.36 million shares outstanding.

>> 7 Top Picks for the Post-Pandemic Economy <<

Nearly 1.50% of Intra-Cellular Therapies Inc.’s shares belong to company insiders and institutional investors own 91.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.69 million shares as on Dec 14, 2021, resulting in a short ratio of 7.14. According to the data, the short interest in Intra-Cellular Therapies Inc. (ITCI) stood at 4.53% of shares outstanding as of Dec 14, 2021; the number of short shares registered in Nov 14, 2021 reached 3.69 million. The stock has fallen by -13.34% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ITCI stock heading into the next quarter.